WallStreetZenWallStreetZen

NASDAQ: MCRB
Seres Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MCRB

Based on 1 analyst offering 12 month price targets for Seres Therapeutics Inc

Min Forecast
$22.00+31.11%
Avg Forecast
$22.00+31.11%
Max Forecast
$22.00+31.11%

Should I buy or sell MCRB stock?

Based on 1 analyst offering ratings for Seres Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although MCRB's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates MCRB as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their MCRB stock forecasts and price targets.

MCRB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-24

1 of 1

Forecast return on equity

Is MCRB forecast to generate an efficient return?

Company
N/A
Industry
254.36%
Market
227.38%

Forecast return on assets

Is MCRB forecast to generate an efficient return on assets?

Company
N/A
Industry
89.85%

MCRB earnings per share forecast

What is MCRB's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.71+208.22%
Avg 2 year Forecast
-$8.89-3,967.13%
Avg 3 year Forecast
-$9.92-4,415.04%

MCRB revenue forecast

What is MCRB's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$272.0k-22.51%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$0.0-100%

MCRB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MCRB$16.78$22.00+31.11%Strong Buy
CGEN$1.65N/AN/A
BDTX$2.71$9.20+239.48%Strong Buy
CGTX$1.68$3.33+98.39%Strong Buy
CHRS$1.29$4.00+210.08%Strong Buy
View Top Biotech Stocks

Seres Therapeutics Stock Forecast FAQ

Is Seres Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: MCRB) stock is to Strong Buy MCRB stock.

Out of 1 analyst, 1 (100%) are recommending MCRB as a Strong Buy, 0 (0%) are recommending MCRB as a Buy, 0 (0%) are recommending MCRB as a Hold, 0 (0%) are recommending MCRB as a Sell, and 0 (0%) are recommending MCRB as a Strong Sell.

If you're new to stock investing, here's how to buy Seres Therapeutics stock.

What is MCRB's earnings growth forecast for 2025-2027?

(NASDAQ: MCRB) Seres Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.62%.

Seres Therapeutics's earnings in 2025 is $5,394,000.On average, 6 Wall Street analysts forecast MCRB's earnings for 2025 to be $6,413,077, with the lowest MCRB earnings forecast at $443,279, and the highest MCRB earnings forecast at $12,728,452. On average, 5 Wall Street analysts forecast MCRB's earnings for 2026 to be -$80,463,359, with the lowest MCRB earnings forecast at -$85,907,554, and the highest MCRB earnings forecast at -$72,856,141.

In 2027, MCRB is forecast to generate -$89,783,082 in earnings, with the lowest earnings forecast at -$94,507,175 and the highest earnings forecast at -$83,589,836.

What is MCRB's revenue growth forecast for 2025-2027?

(NASDAQ: MCRB) Seres Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.81%.

Seres Therapeutics's revenue in 2025 is $351,000.On average, 6 Wall Street analysts forecast MCRB's revenue for 2025 to be $2,460,680, with the lowest MCRB revenue forecast at $0, and the highest MCRB revenue forecast at $3,799,538. On average, 5 Wall Street analysts forecast MCRB's revenue for 2026 to be $0, with the lowest MCRB revenue forecast at $0, and the highest MCRB revenue forecast at $0.

In 2027, MCRB is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is MCRB's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: MCRB) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 89.85%.

What is MCRB's Price Target?

According to 1 Wall Street analyst that have issued a 1 year MCRB price target, the average MCRB price target is $22.00, with the highest MCRB stock price forecast at $22.00 and the lowest MCRB stock price forecast at $22.00.

The Wall Street analyst predicted that Seres Therapeutics's share price could reach $22.00 by Sep 24, 2026. The average Seres Therapeutics stock price prediction forecasts a potential upside of 31.11% from the current MCRB share price of $16.78.

What is MCRB's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: MCRB) Seres Therapeutics's current Earnings Per Share (EPS) is $0.23. On average, analysts forecast that MCRB's EPS will be $0.71 for 2025, with the lowest EPS forecast at $0.05, and the highest EPS forecast at $1.41. On average, analysts forecast that MCRB's EPS will be -$8.89 for 2026, with the lowest EPS forecast at -$9.50, and the highest EPS forecast at -$8.05. In 2027, MCRB's EPS is forecast to hit -$9.92 (min: -$10.45, max: -$9.24).

What is MCRB's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: MCRB) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.